###begin article-title 0
###xml 0 6 <span type="species:ncbi:9606">Humans</span>
Humans Lack iGb3 Due to the Absence of Functional iGb3-Synthase: Implications for NKT Cell Development and Transplantation
###end article-title 0
###begin article-title 1
Starting Over: The Search for Endogenous NKT Cell Ligands
###end article-title 1
###begin p 2
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 180 186 <span type="species:ncbi:9606">humans</span>
###xml 501 505 <span type="species:ncbi:10090">mice</span>
###xml 657 662 <span type="species:ncbi:9606">human</span>
###xml 827 832 <span type="species:ncbi:9606">human</span>
###xml 907 912 <span type="species:ncbi:9606">human</span>
###xml 1061 1066 <span type="species:ncbi:9606">human</span>
###xml 1157 1162 <span type="species:ncbi:9606">human</span>
###xml 1248 1254 <span type="species:ncbi:9606">humans</span>
###xml 1404 1410 <span type="species:ncbi:9606">humans</span>
###xml 1448 1454 <span type="species:ncbi:9606">humans</span>
The glycosphingolipid isoglobotrihexosylceramide, or isogloboside 3 (iGb3), is believed to be critical for natural killer T (NKT) cell development and self-recognition in mice and humans. Furthermore, iGb3 may represent an important obstacle in xenotransplantation, in which this lipid represents the only other form of the major xenoepitope Galalpha(1,3)Gal. The role of iGb3 in NKT cell development is controversial, particularly with one study that suggested that NKT cell development is normal in mice that were rendered deficient for the enzyme iGb3 synthase (iGb3S). We demonstrate that spliced iGb3S mRNA was not detected after extensive analysis of human tissues, and furthermore, the iGb3S gene contains several mutations that render this product nonfunctional. We directly tested the potential functional activity of human iGb3S by expressing chimeric molecules containing the catalytic domain of human iGb3S. These hybrid molecules were unable to synthesize iGb3, due to at least one amino acid substitution. We also demonstrate that purified normal human anti-Gal immunoglobulin G can bind iGb3 lipid and mediate complement lysis of transfected human cells expressing iGb3. Collectively, our data suggest that iGb3S is not expressed in humans, and even if it were expressed, this enzyme would be inactive. Consequently, iGb3 is unlikely to represent a primary natural ligand for NKT cells in humans. Furthermore, the absence of iGb3 in humans implies that it is another source of foreign Galalpha(1,3)Gal xenoantigen, with obvious significance in the field of xenotransplantation.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin title 4

###end title 4
###begin p 5
###xml 231 235 <span type="species:ncbi:10090">mice</span>
###xml 240 246 <span type="species:ncbi:9606">humans</span>
###xml 343 348 <span type="species:ncbi:9606">human</span>
###xml 517 523 <span type="species:ncbi:9606">humans</span>
###xml 672 677 <span type="species:ncbi:9606">human</span>
###xml 763 768 <span type="species:ncbi:9606">human</span>
###xml 893 898 <span type="species:ncbi:9606">human</span>
###xml 1024 1030 <span type="species:ncbi:9606">humans</span>
###xml 1096 1101 <span type="species:ncbi:9606">human</span>
###xml 1129 1134 <span type="species:ncbi:9606">human</span>
###xml 1158 1163 <span type="species:ncbi:9606">human</span>
###xml 1222 1226 <span type="species:ncbi:9823">pigs</span>
Identification of endogenous antigens that regulate natural killer T (NKT) cell development and function is a major goal in immunology. Originally the glycosphingolipid, iGb3, was suggested to be the main endogenous ligand in both mice and humans. However, recent studies have challenged this hypothesis. From a xenotransplantation (animal to human transplants) perspective, iGb3 expression is also important as it represents another form of the major xenoantigen Galalpha(1,3)Gal. In this study, we assessed whether humans expressed a functional iGb3 synthase (iGb3S), the enzyme responsible for lipid synthesis. We showed that spliced iGb3S mRNA was not detected in any human tissue analysed. Furthermore, chimeric molecules composed of the catalytic domain of human iGb3S were unable to synthesize iGb3 lipid, due to at least one amino acid substitution. We also demonstrated that purified human anti-Gal antibodies bound iGb3 lipid and mediated destruction of cells transfected to express iGb3. A nonfunctional iGb3S in humans has two major consequences: (1) iGb3 is unlikely to be a natural human NKT ligand and (2) natural human anti-Gal antibodies in human serum could react with iGb3 on the surface of organs from pigs, marking these tissues for immunological destruction.
###end p 5
###begin p 6
###xml 62 68 <span type="species:ncbi:9606">humans</span>
Controversy surrounds the glycolipid iGb3. Our data show that humans do not express this lipid. This has important implications in natural killer T cell development, self-recognition, and transplantation.
###end p 6
###begin title 7
Introduction
###end title 7
###begin p 8
###xml 324 325 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b001">1</xref>
###xml 514 515 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b002">2</xref>
###xml 648 649 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b002">2</xref>
###xml 726 727 706 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b003">3</xref>
###xml 255 261 <span type="species:ncbi:9606">humans</span>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
###xml 640 646 <span type="species:ncbi:9606">humans</span>
###xml 718 724 <span type="species:ncbi:9606">humans</span>
###xml 800 806 <span type="species:ncbi:9606">humans</span>
Identification of endogenous antigens that regulate NKT cell development and self-recognition represents a major goal in immunology. This unique population of T cells is characterised by expression of an invariant Valpha14Jalpha18 TCR-Valpha24Jalpha18 in humans-and the recognition of glycolipid antigens presented by CD1d [1]. When activated, natural killer T (NKT) cells regulate immune responses through their ability to produce large amounts of cytokines such as interferon (IFN)-gamma and interleukin (IL)-4 [2]. NKT cell deficiencies are associated with a range of diseases, including cancer, autoimmunity, and infection, in mice and humans [2]. This, combined with the fact that NKT cell numbers vary widely in humans [3], highlights the importance of understanding the endogenous antigens in humans that regulate NKT cell development and function.
###end p 8
###begin p 9
###xml 133 134 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b004">4</xref>
###xml 224 225 216 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b005">5</xref>
###xml 226 227 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b006">6</xref>
###xml 386 387 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b007">7</xref>
###xml 1101 1102 1082 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b007">7</xref>
###xml 1408 1409 1389 1390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b008">8</xref>
###xml 1410 1412 1391 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b013">13</xref>
###xml 1533 1535 1514 1516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b012">12</xref>
###xml 1671 1673 1652 1654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b014">14</xref>
###xml 1674 1676 1655 1657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b016">16</xref>
###xml 1701 1703 1682 1684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b016">16</xref>
###xml 1911 1913 1892 1894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b015">15</xref>
###xml 2368 2370 2349 2351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b014">14</xref>
###xml 2371 2373 2352 2354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b017">17</xref>
###xml 2374 2376 2355 2357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b018">18</xref>
###xml 207 211 <span type="species:ncbi:10090">mice</span>
###xml 216 222 <span type="species:ncbi:9606">humans</span>
###xml 777 782 <span type="species:ncbi:10090">mouse</span>
###xml 787 792 <span type="species:ncbi:9606">human</span>
###xml 912 917 <span type="species:ncbi:9606">human</span>
###xml 1067 1072 <span type="species:ncbi:9606">human</span>
###xml 1250 1254 <span type="species:ncbi:10090">mice</span>
###xml 1259 1265 <span type="species:ncbi:9606">humans</span>
###xml 1381 1386 <span type="species:ncbi:10090">mouse</span>
###xml 1391 1396 <span type="species:ncbi:9606">human</span>
###xml 1527 1531 <span type="species:ncbi:10090">mice</span>
###xml 1665 1669 <span type="species:ncbi:10090">mice</span>
###xml 1730 1735 <span type="species:ncbi:10090">mouse</span>
###xml 1739 1744 <span type="species:ncbi:9606">human</span>
###xml 1969 1973 <span type="species:ncbi:10090">mice</span>
###xml 2110 2114 <span type="species:ncbi:10090">mice</span>
###xml 2217 2221 <span type="species:ncbi:10090">mice</span>
###xml 2411 2416 <span type="species:ncbi:9606">human</span>
###xml 2494 2499 <span type="species:ncbi:9606">human</span>
Initial work demonstrated that alpha-galactosylceramide (alpha-GalCer), a glycosphingolipid originally derived from a marine sponge [4], was a potent agonist for NKT cells in a CD1d-dependent manner in both mice and humans [5,6]. However, the physiological relevance of this in mammalian systems was difficult to understand because alpha-GalCer is not a mammalian product. Zhou et al. [7] demonstrated that a deficiency in the lysosomal enzymes beta-hexaminidase A and B selectively abrogated NKT cell development, suggesting that glycolipid(s) downstream of these enzymes are responsible for NKT cell selection. Experiments to directly test which of the candidate glycolipids were capable of stimulating NKT cells pointed to the glycosphingolipid, isogloboside 3 (iGb3). Both mouse and human fresh NKT cells, and NKT cell hybridomas and lines, responded to iGb3, and furthermore, specific inhibition of iGb3 on human cells, using isolectin B4 (IB4) that should selectively target iGb3 via its terminal Galalpha(1,3)Gal sugars, suggested that iGb3 was also a primary human self-antigen for NKT cells [7]. These data led the authors to suggest that iGb3 was the main endogenous ligand responsible for NKT cell development and self-recognition in both mice and humans. Subsequent studies from independent groups have confirmed that iGb3 is an agonist ligand for at least a subset of mouse and human NKT cells [8-13], and furthermore, that this glycosphingolipid appears to be important for shaping the NKT cell TCR repertoire in mice [12]. However, recent studies have challenged the hypothesis that iGb3 is the primary ligand responsible for NKT cell development in mice [14-16]. One of these studies [16] failed to detect iGb3 in mouse or human thymus, although this study could not exclude the existence of low levels of iGb3, or higher levels of iGb3 expressed by a minor subset of the thymus. Another study [15] demonstrated, by using iGb3 synthase (iGb3S) knockout mice, that NKT cell development was apparently normal, which more strongly suggested that iGb3 is at least not essential for this process in mice. Lastly, two papers have provided evidence that the defect in NKT cell development in Hex-b-deficient mice may be the lysosomal storage disease that occurs with this mutation, thus causing a nonspecific defect in glycolipid processing and presentation [14,17,18]. The ability of iGb3 to activate human NKT cells is not in dispute; what remains in question is the role of iGb3 in human NKT cell biology.
###end p 9
###begin p 10
###xml 934 936 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b019">19</xref>
###xml 993 995 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b019">19</xref>
###xml 1186 1193 1150 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pbio-0060172-t001">Table 1</xref>
###xml 159 162 <span type="species:ncbi:9823">pig</span>
###xml 226 232 <span type="species:ncbi:9606">humans</span>
###xml 808 813 <span type="species:ncbi:9606">human</span>
###xml 1010 1016 <span type="species:ncbi:9606">humans</span>
Another issue of major importance involving iGb3 is from the perspective of xenotransplantation, in which expression of this glycolipid on the cell surface of pig tissue could represent a major problem if it is not present in humans. iGb3 is synthesized by iGb3S, a member of the alpha1,3Gal/GalNAc transferase or Family 6 glycosyltransferases. Other family members include alpha1,3galactosyltransferase (alpha1,3 GT), and the B blood group transferase, which like iGb3S, transfer alphaGal. In contrast, the two other members of the family, A blood group transferase and Forssman synthetase, transfer alphaGalNAc. Members of Family 6 are the only known mammalian glycosyltransferases that transfer either alphaGal or alphaGalNAc in an alpha1,3 linkage to their respective acceptor molecules. Analysis of the human genome shows the genes for the alpha1,3GT, iGb3S, A/B blood group transferase, and the Forssman synthetase are present [19]. Recently, GT6m7, a new Family 6 member, was reported [19]; however, in humans, the gene for this glycosyltransferase contains a premature stop codon in the last exon. Indeed, mutation appears to be common in this family, with varying effects (see Table 1).
###end p 10
###begin p 11
###xml 19 24 <span type="species:ncbi:9606">Human</span>
Characteristics of Human alpha1,3Gal/GalNAc (Family 6) Glycosyltransferases
###end p 11
###begin p 12
###xml 401 403 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b020">20</xref>
###xml 119 125 <span type="species:ncbi:9606">humans</span>
###xml 297 303 <span type="species:ncbi:9606">humans</span>
In a similar fashion to ABO blood groups, in which natural antibodies are made to specificities that individuals lack, humans produce anti-alphaGal antibodies as a consequence of nonfunctional, or nontranslated enzymes. The evolutionary event that led to selection of the alphaGal-ve phenotype in humans is not clear, but selective pressure of the alphaGal+ve protozoan parasites has been postulated [20].
###end p 12
###begin p 13
###xml 212 214 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b021">21</xref>
###xml 295 297 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b022">22</xref>
###xml 366 368 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b023">23</xref>
###xml 424 427 404 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 609 610 585 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b007">7</xref>
###xml 178 181 <span type="species:ncbi:9823">pig</span>
###xml 185 190 <span type="species:ncbi:9606">human</span>
###xml 289 293 <span type="species:ncbi:9823">pigs</span>
###xml 428 432 <span type="species:ncbi:9823">pigs</span>
###xml 451 457 <span type="species:ncbi:9606">humans</span>
###xml 507 512 <span type="species:ncbi:9606">human</span>
###xml 714 719 <span type="species:ncbi:9606">human</span>
###xml 858 864 <span type="species:ncbi:9606">humans</span>
It is well known that the presence of the Galalpha(1,3)Gal xenoepitope, synthesized by alpha1,3galactosyltransferase (alpha1,3GT), causes hyperacute rejection of donor organs in pig-to-human xenotransplantation [21]. To avoid this problem, the alpha1,3GT gene has recently been deleted in pigs [22]. However, there is still low-level expression of Galalpha(1,3)Gal [23], presumably synthesized by iGb3S. Thus, organs from GT-/- pigs transplanted into humans may still potentially be subject to rejection by human natural antibodies to Galalpha(1,3)Gal in the form of iGb3. The study from Zhou and colleagues [7] provided data suggesting that this is unlikely to pose an immediate problem, because they showed that human anti-Gal antibodies did not react with iGb3, presumably because it was a self-ligand that caused deletion of iGb3-reactive lymphocytes in humans. Thus, although there is clearly a significant level of controversy surrounding iGb3, the fact remains that there are compelling results both for and against a role for iGb3 in NKT cell development. For the sake of understanding the factors that regulate this process, as well as whether iGb3 poses an additional problem for xenotransplantion, further studies are required to resolve this issue.
###end p 13
###begin p 14
###xml 48 50 48 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b024">24</xref>
###xml 264 266 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b025">25</xref>
###xml 407 415 396 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g001">Figure 1</xref>
###xml 30 35 <span type="species:ncbi:10090">mouse</span>
We recently characterized the mouse iGb3S cDNA [24] that encodes the enzyme that synthesizes the Galalpha(1,3)Gal xenoepitope on iGb3 by catalysing the transfer of donor sugar from UDP-Gal in an alpha-1,3 linkage to its acceptor molecule Galbeta(1,4)Glc-ceramide [25]. This reaction is the first step in the isoglobo-series pathway, which also results in the generation of iGb4 and isoForssman glycolipids (Figure 1).
###end p 14
###begin title 15
Lacosylceramide (Lac-Cer) Is the Starting Material for the Synthesis of Glycolipids via Two Distinct Pathways, the Isoglobo and Globo Series
###end title 15
###begin p 16
The major difference between the two pathways is that in the isoglobo series, iGb3S transfers an alphaGal in an alpha1,3 linkage, whereas in the globo series, Gb3S transfers an alphaGal in an alpha1,4 linkage. The relevant enzymes that catalyse the reactions to generate the different glycolipids are shown in italics. The antibodies that are used to detect these products are shown in bold.
###end p 16
###begin p 17
###xml 68 73 <span type="species:ncbi:9606">human</span>
###xml 182 186 <span type="species:ncbi:9823">pigs</span>
###xml 253 258 <span type="species:ncbi:9606">human</span>
###xml 297 302 <span type="species:ncbi:9606">human</span>
Here, we have examined iGb3S expression and functional potential in human tissues. Moreover, to assess whether iGb3 might represent a xenoantigen that remains in alpha1,3GT knockout pigs, we investigated whether iGb3 glycolipid is recognized by natural human anti-Gal antibodies present in normal human serum, and we also determined whether cells expressing this glycolipid on the cell surface are readily targeted for complement-mediated lysis.
###end p 17
###begin title 18
Results
###end title 18
###begin title 19
###xml 42 47 <span type="species:ncbi:9606">Human</span>
Spliced iGb3S mRNA Is Not Detected in Any Human Tissue Analysed
###end title 19
###begin p 20
###xml 219 221 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b024">24</xref>
###xml 222 224 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b025">25</xref>
###xml 321 322 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</italic>
###xml 521 523 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b024">24</xref>
###xml 733 741 729 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060172-st001">Table S1</xref>
###xml 1174 1182 1158 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g002">Figure 2</xref>
###xml 1582 1584 1566 1568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b024">24</xref>
###xml 1735 1743 1719 1727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g002">Figure 2</xref>
###xml 1976 1984 1960 1968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g002">Figure 2</xref>
###xml 2236 2244 2220 2228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g002">Figure 2</xref>
###xml 2250 2258 2234 2242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060172-st002">Table S2</xref>
###xml 2564 2572 2548 2556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g002">Figure 2</xref>
###xml 2694 2702 2678 2686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g002">Figure 2</xref>
###xml 114 120 <span type="species:ncbi:9606">humans</span>
###xml 142 145 <span type="species:ncbi:10116">rat</span>
###xml 150 155 <span type="species:ncbi:10090">mouse</span>
###xml 241 246 <span type="species:ncbi:9606">human</span>
###xml 391 394 <span type="species:ncbi:10116">rat</span>
###xml 399 404 <span type="species:ncbi:10090">mouse</span>
###xml 491 496 <span type="species:ncbi:9606">human</span>
###xml 671 676 <span type="species:ncbi:9606">human</span>
###xml 794 799 <span type="species:ncbi:9606">human</span>
###xml 961 964 <span type="species:ncbi:10116">rat</span>
###xml 969 974 <span type="species:ncbi:10090">mouse</span>
###xml 1151 1156 <span type="species:ncbi:9606">human</span>
###xml 1226 1231 <span type="species:ncbi:9606">human</span>
###xml 1571 1576 <span type="species:ncbi:10090">mouse</span>
###xml 1646 1651 <span type="species:ncbi:9606">human</span>
###xml 1786 1791 <span type="species:ncbi:9606">human</span>
###xml 2671 2676 <span type="species:ncbi:9606">human</span>
Several lines of evidence from our studies of the Galalpha(1,3)Gal epitope suggest that iGb3S is not expressed in humans. In contrast to both rat and mouse, in which the iGb3S gene is transcribed and the RNA processed [24,25], analysis of a human multiple tissue northern blot did not detect iGb3S mRNA (unpublished data). Furthermore, anti-Gal monoclonal antibodies (mAbs) that detect both rat and mouse iGb3 on tissues and cell lines do not react with a range of both normal and malignant human tissues and cell lines [24] (and our unpublished data). To examine expression of iGb3S mRNA in greater detail, reverse-transcription PCR (RT-PCR) was used to analyse several human tissues. Oligonucleotide primers for these experiments (Table S1) were designed based on the exon arrangement of the human iGb3S gene, established by the analysis of Genbank DNA sequences. RNA from heart, kidney, spleen, lung, and thymus (the latter two tissues express iGb3S in both rat and mouse) generated a product of the correct size (approximately550 bp) with forward and reverse primers within exon five (unpublished data). A product was also obtained from cDNA from human dendritic cells (Figure 2B, lane 6). Some products were confirmed as human iGb3S by direct sequencing (unpublished data). However, generation of products within an exon may be due to genomic DNA or heteronuclear RNA; therefore, amplification across exon boundaries is required to show the presence of mRNA. We have previously shown that iGb3S mRNA can be successfully used as a template for cross-exon RT-PCR from mouse RNA [24]. Despite exhaustive attempts (at least 50 times) to amplify human iGb3S using a combination of primers spanning all five exons in different tissues (Figure 2A), products were either not obtained from human template or the size of several of the PCR products corresponded to that expected from genomic DNA rather than spliced mRNA. The data shown are the amplification from dendritic cells (Figure 2B); however, similar results were also obtained from all tissues examined. Primers across exon 1 to 3, exons 1 to 4, and exons 2 to 4 yielded products expected from amplification of genomic DNA rather than spliced RNA (lanes 1, 2, and 4, respectively, Figure 2B and Table S2). The products observed in lanes 6 and 7 are within a single exon and could represent either genomic or mRNA products as there is no splicing over this region of the iGb3S gene. Despite using numerous primer combinations, including forward primers from exons 2, 3, or 4 with a reverse primer from exon 5 (Figure 2C), we were unable to detect any products of the correct size to suggest spliced iGb3S mRNA in any human tissue examined (Figure 2D), even when a high cycle number (up to 40) was used (unpublished data). As expected, products were not observed when template was omitted.
###end p 20
###begin title 21
###xml 38 43 <span type="species:ncbi:9606">Human</span>
Spliced iGb3S mRNA Is Not Detected in Human Tissues
###end title 21
###begin p 22
###xml 56 61 <span type="species:ncbi:9606">human</span>
(A) Schematic representation of the exon arrangement of human iGb3 synthase. Numbers (1-7) in the left-hand column denote the different primer combinations used in PCR analysis. Arrows define both primer direction and specific binding exons.
###end p 22
###begin p 23
(B) PCR products generated from dendritic cell cDNA template using the primer combinations described above. Numbers on the left are size markers (kilobases).
###end p 23
###begin p 24
###xml 56 61 <span type="species:ncbi:9606">human</span>
(C) Schematic representation of the exon arrangement of human iGb3S. Numbers (1-4) in the left-hand column denote the different primer combinations used in PCR analysis. Arrows define both primer direction and specific binding exons.
###end p 24
###begin p 25
(D) PCR products generated from dendritic cell cDNA template using the primer combinations described above. Numbers on the left are size markers (kilobases). Using these and other primer combinations, these PCR experiments were repeated several times.
###end p 25
###begin title 26
###xml 9 14 <span type="species:ncbi:9606">Human</span>
Chimeric Human iGb3S Molecules Do Not Synthesize the Galalpha(1,3)Gal Xenoepitope
###end title 26
###begin p 27
###xml 309 311 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b024">24</xref>
###xml 635 637 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b026">26</xref>
###xml 997 1005 993 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g003">Figure 3</xref>
###xml 1011 1019 1007 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060172-st003">Table S3</xref>
###xml 1321 1323 1317 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b027">27</xref>
###xml 1678 1680 1666 1668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b028">28</xref>
###xml 1755 1763 1743 1751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g003">Figure 3</xref>
###xml 1855 1857 1839 1841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b028">28</xref>
###xml 2087 2095 2067 2075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g003">Figure 3</xref>
###xml 2276 2284 2252 2260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g003">Figure 3</xref>
###xml 2321 2345 2297 2321 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Bandeiraea simplicifolia</named-content>
###xml 2397 2406 2369 2378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060172-sg001">Figure S1</xref>
###xml 2651 2660 2619 2628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060172-sg002">Figure S2</xref>
###xml 2869 2878 2837 2846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060172-sg002">Figure S2</xref>
###xml 21 26 <span type="species:ncbi:10090">mouse</span>
###xml 129 134 <span type="species:ncbi:9606">human</span>
###xml 226 231 <span type="species:ncbi:10090">mouse</span>
###xml 361 367 <span type="species:ncbi:9606">humans</span>
###xml 898 901 <span type="species:ncbi:10116">rat</span>
###xml 941 946 <span type="species:ncbi:9606">human</span>
###xml 977 982 <span type="species:ncbi:9606">human</span>
###xml 1032 1035 <span type="species:ncbi:10116">rat</span>
###xml 1355 1358 <span type="species:ncbi:10116">rat</span>
###xml 1359 1364 <span type="species:ncbi:9606">human</span>
###xml 1521 1524 <span type="species:ncbi:10116">rat</span>
###xml 1686 1691 <span type="species:ncbi:9606">human</span>
###xml 1742 1747 <span type="species:ncbi:9606">human</span>
###xml 1933 1938 <span type="species:ncbi:9606">human</span>
###xml 1946 1949 <span type="species:ncbi:10116">rat</span>
###xml 1950 1955 <span type="species:ncbi:9606">human</span>
###xml 2068 2073 <span type="species:ncbi:9606">human</span>
###xml 2148 2153 <span type="species:ncbi:9606">human</span>
###xml 2201 2204 <span type="species:ncbi:10116">rat</span>
###xml 2205 2210 <span type="species:ncbi:9606">human</span>
###xml 2440 2445 <span type="species:ncbi:9606">human</span>
From our experience, mouse iGb3S mRNA is expressed at low levels and is difficult to amplify. Therefore, our inability to detect human iGb3S mRNA was not conclusive evidence that it was absent. Transfection of CHOP cells with mouse iGb3S cDNA results in high level expression of its product Galalpha(1,3)Gal [24]. We used the same approach to determine whether humans express functional iGb3S. In vitro functional studies indicate that the catalytic domain of iGb3S (which represents 75% of the entire molecule) is encoded by two exons, a small exon (exon 4) and a larger one (exon 5) encoding the major part of the functional domain [26]. Soluble forms of the truncated catalytic domain of several members of the glycosyltransferase family have been shown to be enzymatically active. Using splice overlap extension PCR, we initially generated a chimeric molecule in which exon 5 of the functional rat iGb3S was substituted with that of the human iGb3S homolog (generated from human genomic DNA) (Figure 3A and Table S3). The other rat exons encode the cytoplasmic tail, transmembrane domain, and stalk that anchors the molecule in the lipid bilayer. This approach of exchanging catalytic domains to examine function has been successfully used with Forssman synthetase, another member of this glycosyltransferase family [27]. The ability of this chimeric rat/human(exon5)-iGb3S molecule to synthesize Galalpha(1,3)Gal was determined by analysis of transfected CHOP cells. As expected, cells transfected with DNA encoding rat iGb3S displayed strong cell surface expression of the Galalpha(1,3)Gal epitope on glycolipid as determined by binding of the monoclonal antibody 15.101 [28] and human anti-Gal immunoglobulin (Ig) purified from normal human serum (Figure 3B). The 15.101 mAb has been shown to bind preferentially to Galalpha(1,3)Gal on iGb3 lipid [28]. The chimeric molecule containing the majority of the catalytic domain of human iGb3S (rat/human(exon5)-iGb3S) was unable to synthesise the Galalpha(1,3)Gal epitope as staining was not observed with 15.101 or human anti-Gal Ig (Figure 3B). A second chimeric molecule comprising the entire human catalytic domain, exon 4 together with exon 5 (rat/human(exon4,5)-iGb3S), was also unable to synthesize Galalpha(1,3)Gal (Figure 3B). Data from several other mAbs and Bandeiraea simplicifolia IB4 lectin that bind the Galalpha(1,3)Gal epitope (Figure S1) support the conclusion that the human iGb3S catalytic domain is not functional. Detection of the FLAG epitope in both chimeric enzymes confirmed that the absence of Galalpha(1,3)Gal synthesis was not due to impaired translation or expression (Figure S2A). As glycosyltransferases are integral membrane proteins of the Golgi complex where oligosaccharides are synthesized, perinuclear staining (Golgi-like) confirmed correct trafficking of the chimeric enzymes (Figure S2B). Staining was not observed with cells transfected with vector alone.
###end p 27
###begin title 28
###xml 9 12 <span type="species:ncbi:10116">Rat</span>
###xml 13 18 <span type="species:ncbi:9606">Human</span>
Chimeric Rat/Human-iGb3S Molecules Are Unable to Synthesize Galalpha(1,3)Gal or IsoForssman
###end title 28
###begin p 29
###xml 25 28 <span type="species:ncbi:10116">rat</span>
###xml 45 48 <span type="species:ncbi:10116">rat</span>
###xml 49 54 <span type="species:ncbi:9606">human</span>
###xml 73 76 <span type="species:ncbi:10116">rat</span>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 99 102 <span type="species:ncbi:10116">Rat</span>
###xml 138 143 <span type="species:ncbi:9606">human</span>
(A) Schematic diagram of rat iGb3S, chimeric rat/human(exon5)-iGb3S, and rat/human(exon4,5)-iGb3S. Rat exons are shaded grey; substituted human exons are unshaded.
###end p 29
###begin p 30
###xml 102 105 <span type="species:ncbi:10116">rat</span>
###xml 106 111 <span type="species:ncbi:9606">human</span>
###xml 129 132 <span type="species:ncbi:10116">rat</span>
###xml 133 138 <span type="species:ncbi:9606">human</span>
###xml 234 239 <span type="species:ncbi:9606">human</span>
(B) Cell surface Galalpha(1,3)Gal expression after transfection with DNA encoding chimeric molecules (rat/human(exon5)-iGb3S and rat/human(exon4,5)-iGb3S) following staining with either the anti-Galalpha(1,3)Gal mAb 15.101 or natural human anti-Gal antibodies. The data are representative of five experiments.
###end p 30
###begin p 31
###xml 91 94 <span type="species:ncbi:10116">rat</span>
###xml 128 131 <span type="species:ncbi:10116">rat</span>
###xml 132 137 <span type="species:ncbi:9606">human</span>
###xml 155 158 <span type="species:ncbi:10116">rat</span>
###xml 159 164 <span type="species:ncbi:9606">human</span>
(C) IsoForssman and Galalpha(1,3)Gal expression following cotransfection with DNA encoding rat iGb3S or the chimeric molecules (rat/human(exon5)-iGb3S and rat/human(exon4,5)-iGb3S) and Forssman synthetase (FS). Cells were stained with either the anti-Forssman mAb or the Galalpha(1,3)Gal mAb 15.101. The data are representative of two experiments. Background staining with secondary antibody alone is shown by the dotted histograms in each panel.
###end p 31
###begin title 32
The Absence of iGb3 Staining Is Not Due to Antibody Inaccessibility or It Acting as a Precursor to Generate IsoForssman
###end title 32
###begin p 33
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b025">25</xref>
###xml 319 327 319 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g001">Figure 1</xref>
###xml 759 767 759 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g003">Figure 3</xref>
###xml 1005 1013 1001 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g003">Figure 3</xref>
###xml 1278 1279 1270 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</italic>
###xml 711 714 <span type="species:ncbi:10116">rat</span>
###xml 894 897 <span type="species:ncbi:10116">rat</span>
###xml 898 903 <span type="species:ncbi:9606">human</span>
###xml 921 924 <span type="species:ncbi:10116">rat</span>
###xml 925 930 <span type="species:ncbi:9606">human</span>
###xml 1105 1110 <span type="species:ncbi:9606">human</span>
To explore the unlikely possibility that iGb3 staining was not observed due to antibody inaccessibility, an alternative detection method was used. Synthesis of iGb3 is the initial step for the formation of the isoglobo-series glycolipid pathway, and iGb3 is the precursor to iGb4 and, ultimately, isoForssman [25] (see Figure 1). To examine whether iGb3 was synthesized, a complementation assay in CHOP cells, which lack both iGb3S and Forssman synthetase (FS), was used to determine whether coexpression of chimeric iGb3S with FS results in expression of isoForssman glycolipid. As expected, cells transfected with FS alone did not stain for isoForssman (unpublished data), whereas cells transfected with both rat iGb3S and FS were positive for isoForssman (Figure 3C). Expression of Galalpha(1,3)Gal was confirmed by 15.101 binding. Cells cotransfected with either of the chimeric molecules (rat/human (Exon5)-iGb3S or rat/human (Exon4,5)-iGb3S) and FS did not show any detectable isoForssman staining (Figure 3C). As expected, no Galalpha(1,3)Gal was observed following staining with 15.101. Thus, the human catalytic domain appears to be incapable of generating detectable iGb3 and does not initiate the downstream synthesis of the iGb4 structure required for FS to function.
###end p 33
###begin title 34
###xml 23 28 <span type="species:ncbi:9606">Human</span>
Pro 187 and Asn 252 in Human iGb3S Affect Enzymatic Function
###end title 34
###begin p 35
###xml 997 1005 997 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g004">Figure 4</xref>
###xml 1050 1053 1050 1053 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">252</sub>
###xml 1122 1130 1118 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g004">Figure 4</xref>
###xml 1227 1230 1223 1226 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">187</sub>
###xml 1335 1338 1327 1330 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">221</sub>
###xml 1349 1352 1341 1344 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">280</sub>
###xml 1488 1496 1476 1484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g004">Figure 4</xref>
###xml 1600 1603 1588 1591 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">221</sub>
###xml 1614 1617 1602 1605 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">280</sub>
###xml 1634 1642 1622 1630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g004">Figure 4</xref>
###xml 1723 1726 1711 1714 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">187</sub>
###xml 1923 1926 1907 1910 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">252</sub>
###xml 1929 1937 1913 1921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g004">Figure 4</xref>
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 252 255 <span type="species:ncbi:10116">rat</span>
###xml 280 285 <span type="species:ncbi:9606">human</span>
###xml 393 398 <span type="species:ncbi:9606">human</span>
###xml 583 586 <span type="species:ncbi:10116">rat</span>
###xml 588 593 <span type="species:ncbi:10090">mouse</span>
###xml 599 602 <span type="species:ncbi:9615">dog</span>
###xml 617 622 <span type="species:ncbi:9606">human</span>
###xml 699 704 <span type="species:ncbi:9606">human</span>
###xml 744 749 <span type="species:ncbi:10090">mouse</span>
###xml 753 756 <span type="species:ncbi:9615">dog</span>
###xml 908 911 <span type="species:ncbi:10116">rat</span>
###xml 979 984 <span type="species:ncbi:9606">human</span>
###xml 1045 1048 <span type="species:ncbi:10116">rat</span>
###xml 1166 1171 <span type="species:ncbi:9606">human</span>
###xml 1222 1225 <span type="species:ncbi:10116">Rat</span>
###xml 1330 1333 <span type="species:ncbi:10116">rat</span>
###xml 1344 1347 <span type="species:ncbi:10116">rat</span>
###xml 1477 1480 <span type="species:ncbi:10116">rat</span>
###xml 1595 1598 <span type="species:ncbi:10116">rat</span>
###xml 1609 1612 <span type="species:ncbi:10116">rat</span>
###xml 1718 1721 <span type="species:ncbi:10116">rat</span>
###xml 1918 1921 <span type="species:ncbi:10116">rat</span>
Using site-directed mutagenesis, we analysed which amino acid(s) contributed to the loss of function we observed in human iGb3S. Despite an overall similarity of approximately 72%, there are 77 differences within the catalytic domain of the functional rat iGb3S and nonfunctional human iGb3S, any of which, either alone or in combination, may be involved in the loss of function observed with human iGb3S. The targeted residues were selected by comparison of the aligned amino acid sequences of the iGb3S catalytic domains (exon 4 and 5 encoded) of species known to synthesize iGb3 (rat, mouse, and dog) with that of human. To identify more precise candidates, amino acids were excluded: (1) if the human amino acid was identical to either the mouse or dog, (2) the amino acid residue was different in all four species, or (3) the substitution was with an homologous amino acid. Four of these amino acids in rat exon 5 were selected in these initial studies and mutated to their human equivalent (Figure 4A). The single isolated substitution of rat Y252N resulted in the complete elimination of Galalpha(1,3)Gal staining (Figure 4B), showing that this asparagine in human iGb3S is sufficient to ablate enzymatic function. Rat L187P showed a significant reduction (typically 70%-95%) in Galalpha(1,3)Gal staining, whereas both the rat A221S and rat E280A substitutions showed strong Galalpha(1,3)Gal expression that was comparable with that observed following transfection with rat iGb3S (Figure 4B). As expected, a complementation assay with FS resulted in strong isoForssman staining with both rat A221S and rat E280A substitutions (Figure 4C). A similar high level of isoForssman staining was also observed with the rat L187P substitution, despite there being minimal Galalpha(1,3)Gal expression, thus demonstrating the sensitivity of this method. IsoForssman staining was not observed with cells cotransfected with rat Y252N (Figure 4C).
###end p 35
###begin title 36
###xml 25 28 <span type="species:ncbi:10116">Rat</span>
A Single Substitution in Rat iGb3S Completely Eliminates Galalpha(1,3)Gal Staining
###end title 36
###begin p 37
###xml 47 50 <span type="species:ncbi:10116">rat</span>
###xml 132 135 <span type="species:ncbi:10116">rat</span>
###xml 139 144 <span type="species:ncbi:9606">human</span>
(A) Diagram, based on the crystal structure of rat iGb3S, showing the structure of exons 4 and 5 with the relative positions of the rat to human amino acid substitutions. The arrows represent beta sheets and the cylinders alpha helices.
###end p 37
###begin p 38
###xml 132 135 124 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">187</sub>
###xml 139 142 131 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">221</sub>
###xml 146 149 138 141 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">252</sub>
###xml 157 160 149 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">280</sub>
###xml 103 106 <span type="species:ncbi:10116">rat</span>
###xml 110 115 <span type="species:ncbi:9606">human</span>
(B) Expression of Galalpha(1,3)Gal following staining with the anti-Galalpha(1,3)Gal mAb 15.101 of the rat to human point mutants (L187P, A221S, Y252N, and E280A). Background staining with secondary antibody alone is shown by the dotted histograms in each panel. The data are representative of five experiments.
###end p 38
###begin p 39
###xml 131 134 131 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">187</sub>
###xml 138 141 138 141 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">221</sub>
###xml 145 148 145 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">252</sub>
###xml 156 159 156 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">280</sub>
###xml 103 106 <span type="species:ncbi:10116">rat</span>
###xml 110 115 <span type="species:ncbi:9606">human</span>
(C). IsoForssman expression following cotransfection of Forssman synthetase (FS) with DNA encoding the rat to human point mutants L187P, A221S, Y252N, and E280A. Cells were stained with the anti-Forssman mAb. The data are representative of three experiments. Background staining with secondary antibody alone is shown by the dotted histograms in each panel.
###end p 39
###begin title 40
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human iGb3S Is Inactive because of Multiple Mutations
###end title 40
###begin p 41
###xml 25 28 25 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">252</sub>
###xml 35 38 35 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">187</sub>
###xml 269 272 269 272 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">187</sub>
###xml 278 281 278 281 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">252</sub>
###xml 305 308 305 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">187</sub>
###xml 311 314 311 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">252</sub>
###xml 621 629 617 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g005">Figure 5</xref>
###xml 79 85 <span type="species:ncbi:9606">humans</span>
###xml 179 182 <span type="species:ncbi:10116">rat</span>
###xml 183 188 <span type="species:ncbi:9606">human</span>
###xml 212 215 <span type="species:ncbi:10116">rat</span>
###xml 672 677 <span type="species:ncbi:9606">human</span>
###xml 837 840 <span type="species:ncbi:10116">rat</span>
It is possible that the Y252N and L187P substitutions are not the only ones in humans that influence function. This was examined by reverse mutation of the nonfunctional chimeric rat/human(exon 5)-iGb3S to their rat equivalents with either point mutation alone (i.e., P187L or N252Y), or in combination (P187L+N252Y). A gain of function would suggest these are the primary residues involved in determining whether the transferase is functional. Staining with mAb 15.101 showed no Galalpha(1,3)Gal expression following transfection of CHOP cells with either the single or combined reverse-mutated chimeric cDNA molecules (Figure 5). The implications of these data are that human iGb3S must have multiple mutations that have resulted in its inactivation. Typical strong Galalpha(1,3)Gal expression was observed with cells transfected with rat iGb3S.
###end p 41
###begin title 42
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human iGb3S Appears to Be Inactive because of Multiple Mutations
###end title 42
###begin p 43
###xml 65 68 61 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">187</sub>
###xml 72 75 68 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">252</sub>
###xml 108 111 104 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">187</sub>
###xml 114 117 110 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">252</sub>
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 52 55 <span type="species:ncbi:10116">rat</span>
Galalpha(1,3)Gal expression of the reverse human to rat single (P187L, N252Y) or combined point mutations (P187L+N252Y). Background staining with secondary antibody alone is shown by the dotted histograms in each panel. The data are representative of three experiments.
###end p 43
###begin title 44
###xml 9 14 <span type="species:ncbi:9606">Human</span>
Purified Human Anti-Gal Antibodies Bind iGb3 Lipid
###end title 44
###begin p 45
###xml 65 66 65 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b007">7</xref>
###xml 502 510 498 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g006">Figure 6</xref>
###xml 867 875 851 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g006">Figure 6</xref>
###xml 1114 1122 1090 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g006">Figure 6</xref>
###xml 1146 1154 1122 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g006">Figure 6</xref>
###xml 1267 1275 1243 1251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g006">Figure 6</xref>
###xml 1293 1301 1269 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g006">Figure 6</xref>
###xml 1307 1308 1283 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g006">6</xref>
###xml 92 97 <span type="species:ncbi:9606">human</span>
###xml 203 208 <span type="species:ncbi:9606">human</span>
###xml 268 274 <span type="species:ncbi:9606">humans</span>
###xml 388 393 <span type="species:ncbi:9606">human</span>
###xml 827 832 <span type="species:ncbi:9606">human</span>
###xml 1060 1065 <span type="species:ncbi:9606">human</span>
High-performance thin layer chromatography data from Zhou et al [7] suggested natural mixed human serum antibodies did not recognize iGb3, suggesting that iGb3-reactive B cells had been deleted from the human repertoire, further evidence that iGb3 lipid is present in humans. To test this ourselves, we used a lipid ELISA, and by this approach, demonstrated clear binding of both natural human anti-Galalpha(1,3)Gal antibodies and the mAb 15.101 to purified iGb3 lipid over several antibody dilutions (Figure 6A). Binding was not observed with either anti-CD17 (lactosylceramide) or anti-CD77 (Gb3) mAbs. Furthermore, as a specificity control, treatment of iGb3 lipid with alpha-galactosidase, which specifically removes the terminal alpha(1,3)Gal moiety, resulted in a significant inhibition (up to 60%) of binding by natural human anti-Galalpha(1,3)Gal antibodies (Figure 6B), yet had no effect on anti-CD17 binding to lactosylceramide (no alphaGal moiety) in a parallel assay. Antibody specificity was further demonstrated by the lack of binding of natural human anti-Galalpha(1,3)Gal antibodies to either Gb3 (Figure 6C) or lactosylceramide (Figure 6D). However, as expected specific binding of both anti-CD77 and anti-CD17 mAbs (used at the same dilutions as in Figure 6A) were observed (Figure 6C and 6D, respectively).
###end p 45
###begin title 46
###xml 9 14 <span type="species:ncbi:9606">Human</span>
Purified Human Anti-Galalpha(1,3)Gal Antibodies Bind iGb3 Lipid
###end title 46
###begin p 47
###xml 43 48 <span type="species:ncbi:9606">human</span>
(A) Doubling dilutions of natural purified human anti-Galalpha(1,3)Gal antibodies (0.49 mg/ml) (filled squares) (diluted 1/10) and anti-Galalpha(1,3)Gal mAb 15.101 supernatant (open circles) (diluted 1/2) binding to plate-bound iGb3 lipid. Background binding with anti-CD17 ascites (lactosylceramide) (diluted 1/40) and purified anti-CD77 (Gb3: 0.15 mg/ml) (diluted 1/50) is shown with open squares and closed circles, respectively.
###end p 47
###begin p 48
###xml 45 50 <span type="species:ncbi:9606">human</span>
(B) Percent inhibition in binding of natural human anti-Galalpha(1,3)Gal antibodies to iGb3 lipid following alpha-galactosidase treatment at the dilutions shown. Unfilled columns represent the binding of anti-CD17 to plate-bound lactosylceramide after alpha-galactosidase treatment.
###end p 48
###begin p 49
###xml 38 43 <span type="species:ncbi:9606">human</span>
(C and D) Binding of natural purified human anti-Galalpha(1,3)Gal antibodies (filled squares), anti-CD17 ascites (open squares), and purified anti-CD77 (closed circles) to either plate-bound Gb3 (C) or lactosylceramide (D).
###end p 49
###begin p 50
The data are representative of two experiments.
###end p 50
###begin title 51
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Cells Expressing iGb3 Undergo Complement-Mediated Lysis
###end title 51
###begin p 52
###xml 292 295 284 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;ve</sup>
###xml 370 373 358 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+ve</sup>
###xml 460 468 448 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g007">Figure 7</xref>
###xml 614 622 594 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g007">Figure 7</xref>
###xml 885 893 861 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g007">Figure 7</xref>
###xml 1282 1290 1242 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g007">Figure 7</xref>
###xml 1362 1370 1319 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g007">Figure 7</xref>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 173 178 <span type="species:ncbi:9606">human</span>
###xml 222 227 <span type="species:ncbi:9606">human</span>
###xml 271 276 <span type="species:ncbi:9606">human</span>
###xml 333 338 <span type="species:ncbi:9606">human</span>
###xml 413 419 <span type="species:ncbi:9986">rabbit</span>
###xml 745 750 <span type="species:ncbi:9606">human</span>
A key question that remains to be answered is, if human cells were to express iGb3, would they be susceptible to antibody-dependent complement-mediated lysis due to natural human anti-alphaGal antibodies present in normal human serum (NHS)? In contrast to nontransfected human cells (alphaGal-ve) that do not undergo lysis with NHS, human cells expressing iGb3 (alphaGal+ve) were lysed by NHS (in the presence of rabbit complement) in a dose-dependent manner (Figure 7A). Removal of anti-alphaGal antibodies from NHS by absorption with Galalpha(1,3)Gal coupled to glass beads abolished lysis to background levels (Figure 7A). However, lysis was not affected by NHS absorption with uncoupled glass beads (unpublished data). Furthermore, lysis of human cells expressing iGb3 was re-established when anti-alphaGal IgG antibodies were purified from NHS and used in the cytotoxicity assay (Figure 7A). In addition, this activity could be removed by absorption with Galalpha(1,3)Gal coupled to glass beads (unpublished data). Inhibition experiments verified that Galalpha(1,3)Gal is the epitope that the antibodies recognise, as a significant dose-dependent reduction in lysis was observed by preincubation of both NHS and anti-alphaGal IgG antibodies with Galalpha(1,3)Gal disaccharide (Figure 7B). No inhibition was observed when lactose (Galbeta(1,4)Glc) was used (Figure 7B).
###end p 52
###begin title 53
###xml 29 34 <span type="species:ncbi:9606">Human</span>
Complement-Mediated Lysis of Human Cells Expressing iGb3
###end title 53
###begin p 54
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 78 83 <span type="species:ncbi:9606">human</span>
###xml 228 233 <span type="species:ncbi:9606">human</span>
(A) Percent lysis of human cells expressing iGb3 following addition of normal human serum (filled circles), purified anti-alphaGal IgG antibodies (filled squares) and NHS absorbed on Gal column (open circles) and nontransfected human cells following addition of NHS (open squares). Serum dilution is shown on the horizontal axis. Data are representative of three experiments.
###end p 54
###begin p 55
###xml 35 40 <span type="species:ncbi:9606">human</span>
(B) Percent inhibition of lysis of human cells expressing iGb3 by preincubation of NHS with Galalpha(1,3)Gal disaccharide (closed circles) or lactose (open circles) or purified anti-alphaGal IgG antibodies with Galalpha(1,3)Gal disaccharide (closed squares) or lactose (open squares). Inhibitor dilution is shown on the horizontal axis. Data are representative of two experiments.
###end p 55
###begin title 56
Discussion
###end title 56
###begin p 57
###xml 1073 1085 1065 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sphingomonas</italic>
###xml 1135 1147 1127 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mycobacteria</italic>
###xml 1162 1164 1154 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b029">29</xref>
###xml 1211 1231 1203 1223 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Borrelia burgdorferi</named-content>
###xml 1344 1346 1336 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b030">30</xref>
###xml 1211 1231 <span type="species:ncbi:139">Borrelia burgdorferi</span>
###xml 1235 1240 <span type="species:ncbi:9606">human</span>
###xml 1317 1322 <span type="species:ncbi:9606">human</span>
###xml 1327 1332 <span type="species:ncbi:10090">mouse</span>
Glycolipids represent one of the last molecular frontiers in immunological recognition. Whereas glycolipids are known to be synthesized in the Golgi and are typically expressed on the cell surface, the exact transport pathway(s) for newly synthesized glycolipids is not well defined. However, it is assumed to be similar to glycoproteins and involve vesicular flow from the endoplasmic reticulum through the Golgi complex to the plasma membrane. Glycolipids, particularly exogenous glycolipids, can localize to lysosomal compartments via endocytosis. Similarly, our knowledge of how glycolipids control immune responses and the context in which they are presented by CD1d and recognized by NKT cells is also still very limited. Since the glycolipid, alpha-GalCer, was originally shown to potently stimulate NKT cells in a CD1d-dependent manner, there has been an enormous effort to identify other ligands. Several classes of natural CD1d-binding ligands for NKT cells have been identified, including microbial-derived alpha-linked glycosphingolipids from the nonpathogenic Sphingomonas bacteria and phosphatidylinositol mannoside from Mycobacteria (reviewed in [29]). Recently, a diacylglycerol glycolipid from Borrelia burgdorferi, a human pathogen responsible for Lyme disease, was shown to directly stimulate both human and mouse NKT cells [30]. Although these ligands are all candidates for NKT cell recognition of non-self, none of these are present in normal mammalian cells.
###end p 57
###begin p 58
###xml 346 347 339 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b007">7</xref>
###xml 348 350 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b012">12</xref>
###xml 351 353 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b031">31</xref>
###xml 458 460 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b014">14</xref>
###xml 778 780 768 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b014">14</xref>
###xml 872 873 859 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b007">7</xref>
###xml 943 945 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b014">14</xref>
###xml 1056 1058 1043 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b018">18</xref>
###xml 1105 1107 1092 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b015">15</xref>
###xml 1108 1110 1095 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b016">16</xref>
###xml 1220 1222 1207 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b015">15</xref>
###xml 1303 1306 1290 1293 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1454 1457 1441 1444 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
###xml 306 310 <span type="species:ncbi:10090">mice</span>
###xml 338 344 <span type="species:ncbi:9606">humans</span>
###xml 421 425 <span type="species:ncbi:10090">mice</span>
###xml 494 498 <span type="species:ncbi:10090">mice</span>
###xml 866 870 <span type="species:ncbi:10090">mice</span>
###xml 1137 1142 <span type="species:ncbi:10090">mouse</span>
###xml 1147 1152 <span type="species:ncbi:9606">human</span>
###xml 1307 1311 <span type="species:ncbi:10090">mice</span>
###xml 1458 1462 <span type="species:ncbi:10090">mice</span>
###xml 1515 1520 <span type="species:ncbi:10090">mouse</span>
###xml 1675 1680 <span type="species:ncbi:10090">mouse</span>
The main candidate self glycolipid-antigen is iGb3. The original collective data, primarily based on the use of beta-hexosaminidase-B-deficient mice that are incapable of degrading iGb4 into iGb3 in lysosomes, supported the claim that iGb3 lipid was a principle endogenous ligand for Valpha14 NKT cells in mice and, albeit indirectly, in humans [7,12,31]. The interpretation of data using beta-hexosaminidase-B-deficient mice was contested by Gadola et al. [14], where it was argued that these mice have a generalised lysosomal storage disease that indirectly impaired CD1d loading in lysosomes. Their interpretation was that it was the accumulation of glycolipids in lysosomes, rather than the lack of iGb3, that abrogated NKT cell development. Some of the data in this paper [14] simply conflicted with that of the earlier study of beta-hexosaminidase-B-deficient mice [7], making it difficult to determine which interpretation was correct [14]. Similar suggestions were raised in an independent study of mutations leading to lysosomal storage diseases [18]. Recently, Porubsky et al. and Speak et al. [15,16] failed to detect iGb3 in mouse and human thymus using a biochemical approach. Furthermore, Porubsky et al. [15] reported normal development and function of invariant NKT (iNKT) cells in iGb3S-/- mice. Although the lack of biochemical evidence for iGb3 in thymus might simply be an issue of insufficient sensitivity, the results from the iGb3S-/- mice more strongly challenge the significance of iGb3 in mouse NKT cell development. There is no easy interpretation that incorporates and integrates the findings from the studies for, and against, a role for iGb3 in mouse NKT cell development. In our opinion, this represents one of the most important and controversial issues in the NKT cell field that requires additional input from independent research groups.
###end p 58
###begin p 59
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b007">7</xref>
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b008">8</xref>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b032">32</xref>
###xml 197 198 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b007">7</xref>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b016">16</xref>
###xml 876 878 876 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b033">33</xref>
###xml 879 881 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b034">34</xref>
###xml 1098 1099 1098 1099 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sup>
###xml 3 9 <span type="species:ncbi:9606">humans</span>
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 133 138 <span type="species:ncbi:9606">human</span>
###xml 251 256 <span type="species:ncbi:9606">human</span>
###xml 347 352 <span type="species:ncbi:9606">human</span>
###xml 363 368 <span type="species:ncbi:9606">human</span>
###xml 758 761 <span type="species:ncbi:10116">rat</span>
###xml 794 799 <span type="species:ncbi:9606">human</span>
###xml 1022 1027 <span type="species:ncbi:9606">human</span>
In humans, synthetically derived iGb3 can stimulate human NKT cells to proliferate and produce cytokines [7,8,32] and recognition of human dendritic cell self-antigen can be blocked by IB4 lectin [7]. However, direct biochemical evidence to show that human iGb3 is an endogenous NKT cell ligand has been lacking. Although iGb3 was not detected in human thymus or human dendritic cells using a high-performance liquid chromatography (HPLC) assay, this assay had a detection limit of 1% iGb3 to 99% Gb3, which does not exclude the presence of iGb3 at low but still biologically significant levels [16]. Indeed, during review of this manuscript, two publications from Li et al., claimed to be able to discriminate iGb3 from Gb3 (in artificial mixtures and from rat cells) and identified iGb4 from human paediatric thymi, using electrospray ionisation-ion trap mass spectrometry [33,34]. Although these analyses are at odds with our own, they have yet to conclusively demonstrate immunologically significant levels of iGb3 in human tissue. Specifically, the formal possibility remains that the minor MSn mass spectral signature for iGb4 detected in these studies is derived from related tetraglycosylceramides, as acknowledged by these investigators. Alternatively, the very low levels of iGb4 detected in these analyses may be derived from dietary sources and distributed throughout the body via lipoprotein particles.
###end p 59
###begin p 60
###xml 825 827 813 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b035">35</xref>
###xml 828 830 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b036">36</xref>
###xml 985 987 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b037">37</xref>
###xml 988 989 960 961 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</bold>
###xml 1398 1400 1366 1368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b038">38</xref>
###xml 1838 1840 1802 1804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b039">39</xref>
###xml 1893 1894 1857 1858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b007">7</xref>
###xml 1895 1897 1859 1861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b032">32</xref>
###xml 2208 2216 2172 2180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pbio-0060172-g007">Figure 7</xref>
###xml 35 41 <span type="species:ncbi:9606">humans</span>
###xml 103 109 <span type="species:ncbi:9606">humans</span>
###xml 160 163 <span type="species:ncbi:9823">pig</span>
###xml 284 290 <span type="species:ncbi:9606">humans</span>
###xml 396 400 <span type="species:ncbi:9823">pigs</span>
###xml 519 523 <span type="species:ncbi:9823">pigs</span>
###xml 786 789 <span type="species:ncbi:9823">pig</span>
###xml 816 823 <span type="species:ncbi:9557">baboons</span>
###xml 842 847 <span type="species:ncbi:9606">human</span>
###xml 953 958 <span type="species:ncbi:9606">human</span>
###xml 1029 1034 <span type="species:ncbi:9606">human</span>
###xml 1078 1082 <span type="species:ncbi:9823">pigs</span>
###xml 1577 1580 <span type="species:ncbi:9823">pig</span>
###xml 1749 1755 <span type="species:ncbi:9606">humans</span>
###xml 1876 1881 <span type="species:ncbi:9606">human</span>
###xml 2018 2021 <span type="species:ncbi:9823">pig</span>
###xml 2254 2257 <span type="species:ncbi:9823">pig</span>
###xml 2585 2588 <span type="species:ncbi:9823">pig</span>
###xml 2723 2727 <span type="species:ncbi:9823">pigs</span>
###xml 2895 2901 <span type="species:ncbi:9606">humans</span>
###xml 3054 3057 <span type="species:ncbi:9823">pig</span>
###xml 3189 3194 <span type="species:ncbi:9606">human</span>
###xml 3233 3238 <span type="species:ncbi:9606">human</span>
The presence or absence of iGb3 in humans has potential major implications for xenotransplantation. If humans express iGb3S, iGb3 lipid present on transplanted pig tissues will not be "seen" as foreign and therefore would not represent a drawback for xenotransplantation. However, as humans do not express functional iGb3S (reported herein), then the presence of lipid-linked Galalpha(1,3)Gal in pigs, synthesized by iGb3S, may pose a serious risk to successful xenotransplantation, even when using alpha1,3GT knockout pigs as donors (which were specifically generated to eliminate Galalpha(1,3)Gal epitopes for xenotransplantation purposes). What are the implications of this in a transplant setting? Currently, we know that expression of iGb3 does not mediate hyperacute rejection of pig tissues transplanted into baboons [35,36]. However, human serum has at least a 4-fold higher level of natural anti-Galalpha(1,3)Gal antibodies (approximately1% of human IgG) than other primates [37], so this may not directly represent the human situation. Furthermore, iGb3 expression in pigs may have more serious consequences in the later phases of graft rejection. Firstly, changes in the affinity/avidity of the elicited antibodies may cause tissue damage by complement fixation. It is clear that the level of anti-Galalpha(1,3)Gal antibody is critical for the speed of rejection in experimental models [38]. Alternatively, elicited anti-Galalpha(1,3)Gal antibodies may contribute to the acute vascular rejection observed when hyperacute rejection is eliminated, such as in knockout pig-to-primate transplants, by activation of endothelial cells via cross-linking of the lipid itself. Pathological features similar to acute vascular rejection are seen in humans when the Gb3 lipid (closely related to iGb3) is cross-linked by bacterial toxins [39]. Secondly, because iGb3 activates human NKT cells [7,32] (in which synthetic, purified. and enzymatically derived iGb3 were all tested), consequently the expression of iGb3 on pig cells could lead to NKT cell activation resulting in destruction of the xenograft. Furthermore, our data clearly show that the anti-Gal antibodies in NHS can lyse iGb3 expressing cells (Figure 7) and therefore any remaining iGb3 on pig cells may be a target for antibody-mediated destruction. Whereas it is clear that the use of heavy immunosuppression can control the later phases of xenograft rejection, the major advantage of xenotransplantation over allotransplantation is the ability to genetically modify the donor. The ultimate goal is to engineer a donor pig such that minimal, or indeed no immunosuppression is required for long-term graft survival. It is likely that genetic modification of pigs may be required to eliminate any effects of iGb3. Only at that stage will other obstacles be revealed. Thus, in formally demonstrating the lack of functional iGb3S in humans, this study alerts transplantation immunologists to a previously unrecognised risk associated with expression of iGb3 glycolipid on alpha1,3GT knockout pig tissues. Expression of this glycolipid could act as a secondary source of Galalpha(1,3)Gal xeno-antigen capable of binding natural human anti-Gal antibodies present in normal human serum and marking these cells for destruction by complement mediated lysis.
###end p 60
###begin p 61
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b040">40</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b014">14</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b016">16</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b017">17</xref>
###xml 422 423 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b007">7</xref>
###xml 131 135 <span type="species:ncbi:10090">mice</span>
###xml 362 366 <span type="species:ncbi:10090">mice</span>
###xml 397 403 <span type="species:ncbi:9606">humans</span>
###xml 488 493 <span type="species:ncbi:9606">human</span>
###xml 709 715 <span type="species:ncbi:9606">humans</span>
In a perspectives article, Godfrey, Pellicci, and Smyth [40] asked whether the search for the elusive NKT cell antigen is over. In mice, in view of several recent publications [14-16], the possible existence of NKT cell-selecting ligands other than iGb3 remains an important consideration [17]. It had generally been assumed that experimental data obtained from mice would be directly relevant to humans, and Zhou et al. [7] provided indirect evidence that iGb3 is also a self-ligand for human NKT cells. However, our new data demonstrate that there appears to be critical differences between the two systems, and suggests that we are a long way from calling off the search for NKT cell-selecting antigens in humans. This remains one of the most important objectives in the field, and will ultimately lead to a better understanding of the factors that regulate NKT cell development and function in health, and in developing novel therapies for the treatment of disease.
###end p 61
###begin title 62
Materials and Methods
###end title 62
###begin title 63
Genomic database searching.
###end title 63
###begin p 64
###xml 191 198 191 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A3GALT2</italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 131 136 <span type="species:ncbi:9606">human</span>
###xml 278 283 <span type="species:ncbi:9606">human</span>
The human genomic iGb3S sequence was obtained from the National Center for Biotechnology Information Web site () and searching the human genomic database. The nucleotide sequence of the gene A3GALT2 (accession number NT 032977) was used, with the exon/intron boundaries for the human iGb3S gene as listed with the sequence.
###end p 64
###begin title 65
PCR.
###end title 65
###begin p 66
###xml 247 256 247 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060172-st001">Tables S1</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060172-st002">S2</xref>
###xml 569 577 569 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060172-st003">Table S3</xref>
###xml 630 633 630 633 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">187</sub>
###xml 637 640 637 640 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">221</sub>
###xml 644 647 644 647 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">252</sub>
###xml 655 658 655 658 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">280</sub>
###xml 715 718 715 718 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">187</sub>
###xml 722 725 722 725 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">252</sub>
###xml 746 749 746 749 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">187</sub>
###xml 752 755 752 755 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">252</sub>
###xml 839 847 839 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pbio-0060172-st004">Table S4</xref>
###xml 24 29 <span type="species:ncbi:9606">human</span>
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 279 282 <span type="species:ncbi:10116">rat</span>
###xml 283 288 <span type="species:ncbi:9606">human</span>
###xml 324 327 <span type="species:ncbi:10116">rat</span>
###xml 336 339 <span type="species:ncbi:10116">rat</span>
###xml 340 345 <span type="species:ncbi:9606">human</span>
###xml 364 367 <span type="species:ncbi:10116">rat</span>
###xml 383 386 <span type="species:ncbi:10116">rat</span>
###xml 387 392 <span type="species:ncbi:9606">human</span>
###xml 429 434 <span type="species:ncbi:9606">human</span>
###xml 448 451 <span type="species:ncbi:10116">rat</span>
###xml 452 457 <span type="species:ncbi:9606">human</span>
###xml 618 621 <span type="species:ncbi:10116">rat</span>
###xml 690 693 <span type="species:ncbi:10116">rat</span>
###xml 694 699 <span type="species:ncbi:9606">human</span>
We were unable to clone human iGb3S from total RNA from adult human tissues (heart, lung, kidney, spleen, and thymus) (Stratagene) or cDNA from dendritic cells using the TITANIUM One-Step RT-PCR Kit (Clontech) with a series of degenerate primers (Tables S1 and S2). The chimeric rat/human molecules included the exchange of rat exon 5 (rat/human(exon5)-iGb3S) and rat exons 4 and 5 (rat/human(exon4,5)-iGb3S) with the equivalent human exon(s). The rat/human chimeras were generated using splice overlap extension PCR. The specific primer combinations used are shown in Table S3. The single amino acid substitutions in rat iGb3S (L187P, A221S, Y252N, and E280A) and the reverse mutations in rat/human(exon5)-iGb3S (P187L, N252Y, and the combined P187L+N252Y) were introduced using the QuikChange site-directed mutagenesis kit (Stratagene) (Table S4). Sequence fidelity, orientation of the insert, and presence of the desired mutation(s) were confirmed by DNA sequencing (Big Dye 3.1; PE-Applied Biosystems).
###end p 66
###begin title 67
 Cell culture, transfection, and antibodies.
###end title 67
###begin p 68
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b041">41</xref>
###xml 562 564 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b024">24</xref>
###xml 565 567 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b042">42</xref>
###xml 573 597 559 583 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="genus-species">Bandeiraea simplicifolia</named-content>
###xml 103 108 <span type="species:ncbi:9606">human</span>
###xml 434 439 <span type="species:ncbi:9606">human</span>
###xml 995 1000 <span type="species:ncbi:9940">sheep</span>
###xml 1006 1011 <span type="species:ncbi:10090">mouse</span>
###xml 1015 1020 <span type="species:ncbi:9606">human</span>
###xml 1049 1054 <span type="species:ncbi:9940">Sheep</span>
###xml 1060 1065 <span type="species:ncbi:9606">human</span>
###xml 1083 1089 <span type="species:ncbi:9986">rabbit</span>
###xml 1095 1100 <span type="species:ncbi:10090">mouse</span>
CHOP cells (Chinese Hamster Ovary cells transformed with Polyoma Large T antigen) [41] and E293 cells (human kidney fibroblasts) were cultured in DMEM (CSL) supplemented with 10% FCS overnight at 37 degreesC. Transfections were with LipofectAMINE Plus (Life Technologies) as recommended by the manufacturer. Cells were examined after 48 h for either cell surface or intracellular expression of Galalpha(1,3)Gal using purified natural human anti-Gal antibodies (0.49 mg/ml), and the anti-Galalpha(1,3)Gal mAbs 15.101, 22.121, 24.7, 25.2, and 8.17 (supernatants) [24,42] and Bandeiraea simplicifolia IB4 lectin. Expression of the FLAG epitope was revealed by staining with the anti FLAG M2 mAb (Sigma). Expression of IsoForssman glycolipid was revealed using an anti-Forssman mAb, FOM-1 (BMA Biomedicals). Expression of lactosylceramide and Gb3 were revealed with anti-CD17 (ascites) and purified anti-CD77 (0.15 mg/ml) mAbs, respectively (Pharmingen). Antibodies were detected with FITC-labelled sheep anti-mouse or human IgG (Dako) or HRP conjugate Sheep anti-human Ig (Silenus) and rabbit anti-mouse Ig (Dako), and analysed either by fluorescence microscopy, flow cytometry (Becton Dickinson FACS Canto II), or lipid ELISA.
###end p 68
###begin title 69
Lipid ELISA and enzyme digestion.
###end title 69
###begin p 70
###xml 217 218 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 772 773 766 767 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 775 776 769 770 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 828 833 822 827 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">405nm</sub>
Porcine lactosylceramide (Calbiochem) and iGb3 (Alexis Biochemicals) were dissolved in methanol at 1 mg/ml and stored at -20 degreesC. The ELISA was performed in 96-well Maxisorb plates (Nunc). Lipids were diluted in n-hexane and used at 500-ng/well, incubated for 1 h in a fume hood to dry; plates were then blocked with 3% BSA/PBS for 2 h and washed x1 with PBS. Primary antibodies, diluted in blocking buffer, were added and incubated for 1 h. After washing x5 with PBS, secondary antibodies, diluted in blocking buffer, were added and incubated for 1 h before washing x8 with PBS. All incubations were carried out at room temperature (RT) on a rocking platform. TMB peroxidase substrate (KPL) was used to develop the plate. Colour development was stopped with 0.18 M H2SO4 and quantitated at an optical density at 405 nm (OD405nm) on an ELISA plate reader. For the enzyme digestion, alpha-galactosidase (Sigma-Aldrich) was diluted in 0.1 M citrate/phosphate buffer (pH 6) and incubated with the lipids overnight at RT, after which an ELISA was performed as described above.
###end p 70
###begin title 71
Complement-mediated lysis.
###end title 71
###begin p 72
###xml 38 40 38 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b028">28</xref>
###xml 427 429 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pbio-0060172-b043">43</xref>
###xml 505 506 500 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 28 31 <span type="species:ncbi:10116">rat</span>
###xml 69 75 <span type="species:ncbi:9986">rabbit</span>
###xml 98 103 <span type="species:ncbi:9606">human</span>
###xml 185 190 <span type="species:ncbi:9606">human</span>
###xml 640 646 <span type="species:ncbi:9986">rabbit</span>
Human E293 cells expressing rat iGb3 [28] were tested for lysis with rabbit complement and normal human sera (NHS, pooled from ten healthy individuals and heat inactivated) or purified human anti-Gal IgG antibodies (prepared by fractionation of the NHS pool on a Protein G Sepharose column (Pharmacia) followed by affinity chromatography on Galalpha(1,3)Gal-coupled macroporous glass beads (Syntesome) as described previously [43]. In brief, 50 mul of antibody at doubling dilutions were added to 2.5 x 105 cells per well in round-bottomed 96-well plates (Greiner), resuspended, and incubated on ice for 30 min. After two washes, 50 mul of rabbit complement, at an appropriate dilution, was added to the cell pellet, resuspended, and incubated at 37 degreesC for 30 min (NHS) or 60 min (purified anti-Gal IgG). Cells were pelleted and resuspended in 400 mul of DMEM/0.5% BSA containing 1 mug/ml propidium iodide (PI; Sigma) and analysed by flow cytometry. Percentage lysis (cytotoxicity) was determined by analysis of 10,000 cells.
###end p 72
###begin p 73
###xml 146 151 <span type="species:ncbi:9606">human</span>
###xml 566 571 <span type="species:ncbi:9606">human</span>
The importance of anti-Gal antibodies for lysis was determined by serum absorption and carbohydrate inhibition: (1) Absorption; 200 mul of NHS or human anti-Gal IgG was added to an equal volume of Galalpha(1,3)Gal-coupled macroporous glass beads or non-coupled beads (control) at 4 degreesC for 30 min; the beads were removed by centrifugation and the absorption step repeated with another aliquot of beads. (2) Carbohydrate inhibition; 25 mul of 20 mM Galalpha(1,3)Gal disaccharide or lactose (control) was serially diluted and mixed with an equal volume of NHS or human anti-Gal IgG at an appropriate dilution (two dilutions less than the 50% titre of the antibody) and incubated at 4 degreesC for 16 h. After both of these treatments, the sera were analysed for complement-mediated lysis.
###end p 73
###begin title 74
Supporting Information
###end title 74
###begin title 75
Cell Surface Staining of Transfected Cells Using Monoclonal Antibodies
###end title 75
###begin p 76
###xml 54 57 <span type="species:ncbi:10116">rat</span>
###xml 65 68 <span type="species:ncbi:10116">rat</span>
###xml 69 74 <span type="species:ncbi:9606">human</span>
###xml 92 95 <span type="species:ncbi:10116">rat</span>
###xml 96 101 <span type="species:ncbi:9606">human</span>
Shows Galalpha(1,3)Gal expression on cells expressing rat iGb3S, rat/human(Exon5)-iGb3S, or rat/human(Exon4,5)-iGb3S following staining with a panel of the anti-Galalpha(1,3)Gal mAbs 22.121, 24.7, 25.2, or 8.17 and the IB4 lectin. Background staining with secondary antibody alone is shown by the dotted histograms in each of the 16 panels. The data are representative of two experiments.
###end p 76
###begin p 77
(69 KB PDF)
###end p 77
###begin p 78
Click here for additional data file.
###end p 78
###begin title 79
Chimeric Protein Expression after Transfection
###end title 79
###begin p 80
###xml 129 132 <span type="species:ncbi:10116">rat</span>
###xml 133 138 <span type="species:ncbi:9606">human</span>
###xml 167 170 <span type="species:ncbi:10116">rat</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
(A) shows a western blot showing anti-FLAG staining of lysates from mock-transfected CHOP cells (lane 1), cells transfected with rat/human(Exon4,5)-iGb3S (lane 2), or rat/human(Exon5)-iGb3S (lane 3). The arrow represents the expected size of the chimeric proteins (40 kD) observed in lanes 2 and 3. The darker, lower band observed in all wells is nonspecific.
###end p 80
###begin p 81
###xml 73 76 <span type="species:ncbi:10116">rat</span>
###xml 94 97 <span type="species:ncbi:10116">rat</span>
###xml 98 103 <span type="species:ncbi:9606">human</span>
###xml 134 137 <span type="species:ncbi:10116">rat</span>
###xml 138 143 <span type="species:ncbi:9606">human</span>
(B) Fluorescence microscopy showing perinuclear (Golgi-like) staining of rat iGb3S (panel 1), rat/human(Exon4,5)-iGb3S (panel 2), and rat/human(Exon5)-iGb3S (panel 3).
###end p 81
###begin p 82
(128 KB PDF)
###end p 82
###begin p 83
Click here for additional data file.
###end p 83
###begin title 84
###xml 32 37 <span type="species:ncbi:9606">Human</span>
###xml 80 83 <span type="species:ncbi:10116">Rat</span>
###xml 84 89 <span type="species:ncbi:9606">Human</span>
Primers Used in PCR Analysis of Human Tissues and in the Generation of Chimeric Rat/Human iGb3S
###end title 84
###begin p 85
(58 KB DOC)
###end p 85
###begin p 86
Click here for additional data file.
###end p 86
###begin title 87
PCR Primer Combinations Used to Analyse Dendritic Cell (DC) cDNA
###end title 87
###begin p 88
The first primer in each of the combinations is the forward primer. Predicted genomic sizes were calculated using the original Genbank data file NT004511.16.
###end p 88
###begin p 89
(31 KB DOC)
###end p 89
###begin p 90
Click here for additional data file.
###end p 90
###begin title 91
###xml 48 51 <span type="species:ncbi:10116">Rat</span>
###xml 52 57 <span type="species:ncbi:9606">Human</span>
Primer Combinations Used in Generating Chimeric Rat/Human-iGb3S-Flag cDNAs
###end title 91
###begin p 92
(29 KB DOC)
###end p 92
###begin p 93
Click here for additional data file.
###end p 93
###begin title 94
###xml 54 57 <span type="species:ncbi:10116">Rat</span>
###xml 77 80 <span type="species:ncbi:10116">Rat</span>
###xml 81 86 <span type="species:ncbi:9606">Human</span>
Primers for Generating Specific Amino Acid Changes in Rat iGb3S and Chimeric Rat/Human(exon5)-iGb3S
###end title 94
###begin p 95
(39 KB DOC)
###end p 95
###begin p 96
Click here for additional data file.
###end p 96
###begin p 97
We thank Mark Smyth for critical reading of the manuscript. Canine Forssman synthetase (FS) cDNA was a gift from Dr. D. B. Haslam, Department of Pediatrics, Washington School of Medicine, St. Louis, United States of America.
###end p 97
###begin title 98
Abbreviations
###end title 98
###begin p 99
Forssman synthetase
###end p 99
###begin p 100
isolectin B4
###end p 100
###begin p 101
immunoglobulin
###end p 101
###begin p 102
isogloboside 3
###end p 102
###begin p 103
isogloboside 3 synthase
###end p 103
###begin p 104
monoclonal antibody
###end p 104
###begin p 105
###xml 7 12 <span type="species:ncbi:9606">human</span>
normal human serum
###end p 105
###begin p 106
natural killer T
###end p 106
###begin p 107
alpha1,3galactosyltransferase
###end p 107
###begin title 108
References
###end title 108
###begin article-title 109
NKT cells: what's in a name
###end article-title 109
###begin article-title 110
Going both ways: immune regulation via CD1d-dependent NKT cells
###end article-title 110
###begin article-title 111
###xml 28 33 <span type="species:ncbi:9606">human</span>
Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples
###end article-title 111
###begin article-title 112
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice
###end article-title 112
###begin article-title 113
CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides
###end article-title 113
###begin article-title 114
CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution
###end article-title 114
###begin article-title 115
Lysosomal glycosphingolipid recognition by NKT cells
###end article-title 115
###begin article-title 116
Conserved and heterogeneous lipid antigen specificities of CD1d-restricted NKT cell receptors
###end article-title 116
###begin article-title 117
Efficient activation of Valpha14 invariant NKT cells by foreign lipid antigen is associated with concurrent dendritic cell-specific self recognition
###end article-title 117
###begin article-title 118
Cutting edge: influence of the TCR Vbeta domain on the selection of semi-invariant NKT cells by endogenous ligands
###end article-title 118
###begin article-title 119
Germline-encoded recognition of diverse glycolipids by natural killer T cells
###end article-title 119
###begin article-title 120
Mechanisms imposing the Vbeta bias of Valpha14 natural killer T cells and consequences for microbial glycolipid recognition
###end article-title 120
###begin article-title 121
Thio-isoglobotrihexosylceramide, an agonist for activating invariant natural killer T cells
###end article-title 121
###begin article-title 122
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases
###end article-title 122
###begin article-title 123
###xml 71 75 <span type="species:ncbi:10090">mice</span>
Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency
###end article-title 123
###begin article-title 124
Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals
###end article-title 124
###begin article-title 125
Chewing the fat on natural killer T cell development
###end article-title 125
###begin article-title 126
Differential alteration of lipid antigen presentation to NKT cells due to imbalances in lipid metabolism
###end article-title 126
###begin article-title 127
Long-term evolution of the CAZY glycosyltransferase 6 (ABO) gene family from fishes to mammals-a birth-and-death evolution model
###end article-title 127
###begin article-title 128
Is malaria linked to the absence of alpha-galactosyl epitopes in Old World primates
###end article-title 128
###begin article-title 129
###xml 59 63 <span type="species:ncbi:9823">pigs</span>
###xml 67 72 <span type="species:ncbi:9606">human</span>
Gal alpha (1,3)Gal, the major xenoantigen(s) recognised in pigs by human natural antibodies
###end article-title 129
###begin article-title 130
###xml 56 60 <span type="species:ncbi:9823">pigs</span>
Production of alpha 1,3-galactosyltransferase-deficient pigs
###end article-title 130
###begin article-title 131
###xml 0 3 <span type="species:ncbi:9823">Pig</span>
Pig cells that lack the gene for alpha1-3 galactosyltransferase express low levels of the gal antigen
###end article-title 131
###begin article-title 132
The molecular basis for galalpha(1,3)gal expression in animals with a deletion of the alpha1,3galactosyltransferase gene
###end article-title 132
###begin article-title 133
Expression cloning of a new member of the ABO blood group glycosyltransferases, iGb3 synthase, that directs the synthesis of isoglobo-glycosphingolipids
###end article-title 133
###begin article-title 134
Mammalian glycosyltransferases: genomic organization and protein structure
###end article-title 134
###begin article-title 135
###xml 24 29 <span type="species:ncbi:9606">human</span>
Characterization of the human Forssman synthetase gene. An evolving association between glycolipid synthesis and host-microbial interactions
###end article-title 135
###begin article-title 136
Carbohydrate residues downstream of the terminal Galalpha(1,3)Gal epitope modulate the specificity of xenoreactive antibodies
###end article-title 136
###begin article-title 137
CD1d ligands: the good, the bad, and the ugly
###end article-title 137
###begin article-title 138
Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria
###end article-title 138
###begin article-title 139
Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections
###end article-title 139
###begin article-title 140
Synthesis and biological evaluation of alpha-galactosylceramide (KRN7000) and isoglobotrihexosylceramide (iGb3)
###end article-title 140
###begin article-title 141
###xml 75 80 <span type="species:ncbi:9606">human</span>
Sensitive detection of isoglobo and globo series tetraglycosylceramides in human thymus by ion trap mass spectrometry
###end article-title 141
###begin article-title 142
Sensitive quantitation of isoglobotriaosylceramide in the presence of isobaric components using electrospray ionization-ion trap mass spectrometry
###end article-title 142
###begin article-title 143
###xml 25 32 <span type="species:ncbi:9557">baboons</span>
###xml 84 88 <span type="species:ncbi:9823">pigs</span>
Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience
###end article-title 143
###begin article-title 144
###xml 59 66 <span type="species:ncbi:9557">baboons</span>
Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue
###end article-title 144
###begin article-title 145
Recent advances in xenotransplantation
###end article-title 145
###begin article-title 146
###xml 95 99 <span type="species:ncbi:10090">mice</span>
Anti-Gal antibody-mediated allograft rejection in alpha1,3-galactosyltransferase gene knockout mice: a model of delayed xenograft rejection
###end article-title 146
###begin article-title 147
Molecular cloning of globotriaosylceramide/CD77 synthase, a glycosyltransferase that initiates the synthesis of globo series glycosphingolipids
###end article-title 147
###begin article-title 148
Immunology. The elusive NKT cell antigen-is the search over
###end article-title 148
###begin article-title 149
###xml 12 31 <span type="species:ncbi:10572">hamster papovavirus</span>
###xml 102 117 <span type="species:ncbi:10029">Chinese hamster</span>
Polyoma and hamster papovavirus large T antigen-mediated replication of expression shuttle vectors in Chinese hamster ovary cells
###end article-title 149
###begin article-title 150
###xml 130 135 <span type="species:ncbi:10090">mouse</span>
Characteristics of immunoglobulin gene usage of the xenoantibody binding to gal-alpha(1,3)gal target antigens in the gal knockout mouse
###end article-title 150
###begin article-title 151
Recognition of an octapeptide sequence by multiple Gal alpha(1,3)Gal-binding proteins
###end article-title 151
###begin article-title 152
###xml 68 73 <span type="species:ncbi:9606">human</span>
Characterization of an alpha 1-3-galactosyltransferase homologue on human chromosome 12 that is organized as a processed pseudogene
###end article-title 152
###begin article-title 153
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 78 84 <span type="species:ncbi:10090">murine</span>
Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal:beta-D-Gal(1,4)-D-GlcNAc alpha(1,3)-galactosyltransferase cDNA
###end article-title 153
###begin article-title 154
###xml 39 44 <span type="species:ncbi:9606">human</span>
Structural basis for the inactivity of human blood group O2 glycosyltransferase
###end article-title 154
###begin article-title 155
Molecular genetic basis of the histo-blood group ABO system
###end article-title 155
###begin p 156
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. DC, JM, and MSS conceived and designed the experiments. DC, EM, HV, and MSS performed the experiments. DC, JM, EM, HV, MJM, DIG, and MSS analyzed the data. DGP, MJM, and DIG contributed reagents/materials/analysis tools. DC, HV, DIG, and MSS wrote the paper.
###end p 156
###begin p 157
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This work was supported by funds obtained from the National Health and Medical Research Council (NHMRC) of Australia, project grant number 315407 and program grant number 454569. MSS and DIG are supported by NHMRC Research Fellowships (MS 266807 and DG 454309). DGP, MJM, and DIG also received support from the National Institutes of Health, National Cancer Institute branch (R01 106377-04) and the Association of International Cancer Research.
###end p 157
###begin p 158
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 158

